185 related articles for article (PubMed ID: 28288848)
21. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
22. Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors.
Qu K; Zaba LC; Satpathy AT; Giresi PG; Li R; Jin Y; Armstrong R; Jin C; Schmitt N; Rahbar Z; Ueno H; Greenleaf WJ; Kim YH; Chang HY
Cancer Cell; 2017 Jul; 32(1):27-41.e4. PubMed ID: 28625481
[TBL] [Abstract][Full Text] [Related]
23. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
24. AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair.
Moyal L; Goldfeiz N; Gorovitz B; Rephaeli A; Tal E; Tarasenko N; Nudelman A; Ziv Y; Hodak E
Invest New Drugs; 2018 Feb; 36(1):1-9. PubMed ID: 28884410
[TBL] [Abstract][Full Text] [Related]
25. Functional Depletion of HSP72 by siRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78.
Fujii K; Idogawa M; Suzuki N; Iwatsuki K; Kanekura T
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681913
[TBL] [Abstract][Full Text] [Related]
26. SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis.
Nihal M; Ahmad N; Wood GS
Cell Cycle; 2014; 13(4):632-40. PubMed ID: 24343700
[TBL] [Abstract][Full Text] [Related]
27. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.
Froehlich TC; Müller-Decker K; Braun JD; Albrecht T; Schroeder A; Gülow K; Goerdt S; Krammer PH; Nicolay JP
Blood; 2019 Aug; 134(5):445-455. PubMed ID: 31167801
[TBL] [Abstract][Full Text] [Related]
28. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
[TBL] [Abstract][Full Text] [Related]
29. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
[TBL] [Abstract][Full Text] [Related]
30. Involvement of p53 Acetylation in Growth Suppression of Cutaneous T-Cell Lymphomas Induced by HDAC Inhibition.
Yu X; Li H; Zhu M; Hu P; Liu X; Qing Y; Wang X; Wang H; Wang Z; Xu J; Tan R; Guo Q; Hui H
J Invest Dermatol; 2020 Oct; 140(10):2009-2022.e4. PubMed ID: 32119867
[TBL] [Abstract][Full Text] [Related]
31. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Jazirehi AR
Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.
Wells CE; Bhaskara S; Stengel KR; Zhao Y; Sirbu B; Chagot B; Cortez D; Khabele D; Chazin WJ; Cooper A; Jacques V; Rusche J; Eischen CM; McGirt LY; Hiebert SW
PLoS One; 2013; 8(7):e68915. PubMed ID: 23894374
[TBL] [Abstract][Full Text] [Related]
34. Down regulation of BCL11B expression inhibits proliferation and induces apoptosis in malignant T cells by BCL11B-935-siRNA.
Huang X; Chen S; Shen Q; Chen S; Yang L; Grabarczyk P; Przybylski GK; Schmidt CA; Li Y
Hematology; 2011 Jul; 16(4):236-42. PubMed ID: 21756541
[TBL] [Abstract][Full Text] [Related]
35. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
[TBL] [Abstract][Full Text] [Related]
36. Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms.
Fang H; Khoury JD; Torres-Cabala CA; Ng SB; Xu J; El Hussein S; Hu S; Vega F; Li S; Tang Z; Tang G; Medeiros LJ; Wang W
Pathology; 2022 Dec; 54(7):893-899. PubMed ID: 35864006
[TBL] [Abstract][Full Text] [Related]
37. GATA-3-dependent Gene Transcription is Impaired upon HDAC Inhibition.
Geng X; Wang C; Abdelrahman S; Perera T; Saed B; Hu YS; Wolfe A; Reneau J; Murga-Zamalloa C; Wilcox RA
Clin Cancer Res; 2024 Mar; 30(5):1054-1066. PubMed ID: 38165708
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC.
Wu CH; Yang CY; Wang L; Gao HX; Rakhshandehroo T; Afghani S; Pincus L; Balassanian R; Rubenstein J; Gill R; Bandyopadhyay S; McCormick F; Moasser M; Ai WZ
J Invest Dermatol; 2021 Feb; 141(2):364-373. PubMed ID: 32603749
[TBL] [Abstract][Full Text] [Related]
39. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
[TBL] [Abstract][Full Text] [Related]
40. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
